• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Research: Proscia AI Predicts Diagnostic Agreement for Melanoma

by Syed Hamza Sohail 11/02/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
JPC Taps Proscia to Modernize World's Largest Human Tissue Repository

What You Should Know:

– Proscia® a provider of digital and computational pathology solutions, has released study results on new artificial intelligence (AI) that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.

– The findings, which were presented at the European Conference on Computer Vision (ECCV) 2022, highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.

Findings Illustrate Promise of Technology to Lower Misdiagnosis Rate for the Deadliest Form of Skin Cancer

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfil the promise of precision care.

Conducted at the University of Florida and Thomas Jefferson University, Proscia’s retrospective study “Using Whole Slide Image Representations from Self-Supervised Contrastive Learning for Melanoma Concordance Regression” demonstrated the AI’s performance on 1,412 whole slide images of skin biopsies. Each image was assessed by three to five dermatopathologists to establish a concordance rate. The R2 correlation between the technology’s predictions and the dermatopathologists’ concordance rates was 0.51.

In addition to this study, Proscia plans to conduct additional research illustrating the potential benefits of AI in helping pathologists to diagnose melanoma, including:

– Lowering the misdiagnosis rate for difficult cases. Melanoma often presents like benign mimickers, causing pathologists to disagree on its diagnosis 40% of the time. As cases are often evaluated by only one pathologist, AI that predicts concordance with multiple experts could help to improve diagnostic accuracy by serving as a second set of eyes. 

– Accelerating turnaround times for critical results. Over 15 million skin biopsies are taken annually in the United States, each of which may display one of the hundreds of diagnoses. AI that predicts diagnostic agreement could flag cases that were likely to be challenging, driving efficiency gains by suggesting additional testing to provide a more complete look prior to pathologist review. 

– Reducing costs and distress for patients. Frequent over-diagnosis of melanoma not only results in additional costs for health systems but also leads patients to pay for unnecessary treatment and cope with the stress of believing they have a life-threatening disease. Increased diagnostic accuracy could help to eliminate these burdens. 

“Melanoma can be very challenging to diagnose,” said Dr. Kiran Motaparthi, Director of Dermatopathology and Clinical Associate Professor of Dermatology at the University of Florida. “Proscia’s technology signals an exciting advancement as pathologists increasingly turn to AI to deliver on their commitment to excellent patient care.”

Proscia’s research also indicates that the same AI could be extended to other diagnoses that demonstrate low pathologist agreement. This includes breast cancer staging as well as Gleason grading of prostate cancer, which is used to evaluate the aggressiveness of the disease. Both often play an important role in informing treatment decisions.

“With this study, we have laid the groundwork for a new use case of AI in pathology that could have a tremendous impact on patient outcomes,” said Sean Grullon, Proscia’s Lead AI Scientist and lead author of the study. “Our technology relies on self-supervised learning to recognize incredibly subtle patterns, demonstrating the power of one of the most advanced approaches in AI.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Breast Cancer, cancer, Digital Pathology, digital transformation, Health Systems, Patient Care, Proscia

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |